MDGLMadrigal Pharmaceuticals Inc
Earnings Recap
• Reported GAAP EPS of -$2.57 up 5.17% YoY • Reported revenue of $321.08M up 210.77% YoY • Madrigal expects robust net sales growth for Rezdiffra in 2026, driven by broad first-line access and increasing disease awareness, further solidifying its market leadership position in MASH treatment.
Bullish
Madrigal Pharmaceuticals achieved nearly $1B in Rezdiffra sales, expanded its MASH pipeline with strategic licenses, and secured patent protection until 2045, strengthening its market leadership and future growth potential.
Bearish
Madrigal Pharmaceuticals reported increased operating expenses and interest expense in 2025, leading to a significant net loss. The company also faces ongoing challenges in market penetration and clinical trial execution.